sellWeak cluster of 1310b5-1 plan
Kathleen A. Rickard sold $767k of VRNA
Chief Medical Officer at Verona Pharma plc. 58,336 shares at an average of $13.14, traded Aug 1, 2025, filed Aug 5, 2025.
Warning score
17Value
$767k
58,336 shares
Holdings after
2,607,472
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +22Trade size$767k at market
- 0Share of holdings soldSold 2.2% of holdings
- +15Cluster13 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-074397, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | MOption exercise Ordinary Shares10b5-1 | +70,888 | $0.00 | $0 | 2,665,808 | Aug 5, 2025 |
| Aug 1, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -58,336 | $13.14 | $767k | 2,607,472 | Aug 5, 2025 |
| Aug 1, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -50,000 | $0.00 | $0 | 200,000 | Aug 5, 2025 |
| Aug 1, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -20,888 | $0.00 | $0 | 146,168 | Aug 5, 2025 |
Related signals
Other insiders at Verona Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Verona Pharma plc | Christina Ackermann director | $24k 1,808 shares | -3% | |
| 36Weak | Verona Pharma plc | Michael Austwick director | $148k 11,288 shares | -47% | |
| 15Weak | Verona Pharma plc | James Aloysius Brady director | $11k 824 shares | -3% | |
| 31Weak | Verona Pharma plc | Kenneth Cunningham director | $142k 10,808 shares | -12% | |
| 30Weak | Verona Pharma plc | Lisa Deschamps director | $124k 9,464 shares | -10% | |
| 20Weak | Verona Pharma plc | David R Ebsworth director | $25k 1,904 shares | -0% | |
| 26Weak | Verona Pharma plc | Martin Edwards director | $142k 10,808 shares | -6% | |
| 26Weak | Verona Pharma plc | Andrew Fisher General Counsel | $126k 9,584 shares | -2% | |
| 27Weak | Verona Pharma plc | Mark W Hahn Chief Financial Officer | $2.7M 208,912 shares | -2% | |
| 21Weak | Verona Pharma plc | Mahendra Shah director | $47k 3,608 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.